摘要
目的 评价ER阳性乳癌根治术后辅助内分泌治疗的效果。方法 ER阳性的根治性术后乳腺癌患者分为内分泌治疗及化疗两组 ,进行全身辅助治疗。内分泌治疗组 194例 ,服用三苯氧胺 (TAM) 5年 ,其中绝经前患者均先切除双侧卵巢后再服用TAM。化疗组 175例 ,主要采用CMFVP或CMF方案。结果 绝经后患者的内分泌治疗组和化疗组 5年无病生存率分别为 78 4%和 45 4%(P <0 0 1) ,5年总生存率分别为 83 3%和 5 2 9% (P <0 0 5 ) ;绝经前患者的内分泌治疗组和化疗组 5年无病生存率分别为 72 8%和 35 7% (P <0 0 1) ,5年总生存率分别为 80 7%和 6 0 0 % (P <0 0 5 )。但是Ⅰ期患者及腋淋巴结转移≥ 8个的患者 ,两者疗效差异无显著性 (P >0 0 5 )。结论 ER阳性乳腺癌术后辅助内分泌治疗效果优于或等于化疗。
Objective To asses the efficacy of adjuvant endocrine therapy in ER positive breast cancer patients after radical mastectomy.Methods 369 eostrogen receptor (ER) positive breast cancer patients were divided into two groups after radical mastectomy: 1. Endocrine group (N 194). The postmenopausal patients in this group received oral tamoxifen (TAM) for five years and the premenopausal patients were first treated with bilateral ovary ablation and, then, given TAM for five years. 2. The chemotherany group patients (N 175) received CTX+MTX+5 Fu+VCR+DXM) (CMFVP) or CTX+MTX+5 Fu (CMF) multi drug chemotherapy. Results Postmenopausal patients in the erdocrine and chemotherapy groups gave discase free survival rates (DFSR) of 78.4% and 45.4% ( P <0.01). Their overall survival rates were 83.3% and 52.9% ( P <0.05). The premenopausal patients gave DFSR of 72.8% and 35.7% ( P <0.01), and their overall survival rates were 80.7% and 60.6% ( P < 0.05). But, no significant difference was observed in the stage Ⅰ patients and those having ≥8 axillary lymph node metastases ( P >0.05).Conclusion For ER positive breast cancer patients, the adjuvant endocrine therapy gives results superior or equal to multi drug chemotherapy after radical mastectomy. [
出处
《中华肿瘤杂志》
CAS
CSCD
北大核心
2001年第5期420-422,共3页
Chinese Journal of Oncology
关键词
乳腺肿瘤
药物治疗
内分泌治疗
ER阳性
Breast neoplasms/therapy
Breast neoplasms/drug therapy
Endocrine therapy
